Kristin S. Price

*This is an algorithmically generated author record based on publicly available information.

Research Subjects

Research Interests

Kristin S. Price has a total of 43 co-authors. Here are the top co-authors by number of shared publications:

Aparna Raj Parikh
Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA
17 shared publications
Bryant H. Chee
University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center (HDFCCC), San Francisco, California. 2
17 shared publications
Carlos Uriel Corvera
Department of Surgery, University of California San Francisco, San Francisco, CA 94143, USA
17 shared publications
Chloe E. Atreya
Helen Diller Family Comprehensive Cancer Center 1 San Francisco, California
17 shared publications
Emily E. Van Seventer
Massachusetts General Hospital Cancer Center Department of Medicine Harvard Medical School Boston MA USA
17 shared publications
Eric K. Nakakura
Department of Surgery, University of California San Francisco, San Francisco, CA 94143, USA
17 shared publications

Latest Publications

Sort by

Open Access
Website
Google Scholar
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment
by Aparna R. Parikh, Bryant H. Chee, Jill Tsai, Thereasa A. Rich, Kristin S. Price, Sonia A. Patel, Li Zhang, Faaiz Ibrahim, Mikaela Esquivel, Emily E. Van Seventer, et al.
Supplementary Figure S1. Schema of ctDNA sampling.
Website
Google Scholar
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S1 from Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment
by Aparna R. Parikh, Bryant H. Chee, Jill Tsai, Thereasa A. Rich, Kristin S. Price, Sonia A. Patel, Li Zhang, Faaiz Ibrahim, Mikaela Esquivel, Emily E. Van Seventer, et al.
Supplementary Figure S1. Schema of ctDNA sampling.
Open Access
Website
Google Scholar
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Data from Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment
by Aparna R. Parikh, Bryant H. Chee, Jill Tsai, Thereasa A. Rich, Kristin S. Price, Sonia A. Patel, Li Zhang, Faaiz Ibrahim, Mikaela Esquivel, Emily E. Van Seventer, et al.
Purpose:Minimal residual disease (MRD) detection can identify the recurrence in patients with colorectal cancer (CRC) following definitive treatment. We evaluated a plasma-only MRD assay to predict recurrence and survival in patients with metastatic CRC who underwent curative intent procedures (surgery and/or radiotherapy), with or without (neo)adjuvant chemotherapy. The primary objective of this study was to assess the correlation of postprocedure tumor cell–free DNA detection status with radiographic disease recurrence.Experimental Design:Preprocedure and postprocedure longitudinal samples were collected from 53 patients and analyzed with a multiomic MRD assay detecting circulating tumor DNA (ctDNA) from genomic and epigenomic signals. Preprocedure and postprocedure ctDNA detection correlated with recurrence-free and overall survival (OS).Results:From 52 patients, 230/233 samples were successfully analyzed. At the time of data cutoff, 36 (69.2%) patients recurred with median follow-up of 31 months. Detectable ctDNA was observed in 19/42 patients (45.2%) with ctDNA analyzed 3 weeks postprocedure. ctDNA detection 3 weeks postprocedure was associated with shorter median recurrence-free survival (RFS; HR, 5.27; 95% CI, 2.31–12.0; P < 0.0001) and OS (HR, 12.83; 95% CI, 3.6–45.9; P < 0.0001). Preprocedure ctDNA detection status was not associated with RFS but was associated with improved OS (HR, 4.65; 95% CI, 1.4–15.2; P = 0.0111). Undetectable ctDNA preprocedure had notable long-term OS, >90% 3 years postprocedure.Conclusions:In this cohort of oligometastatic CRC, detection of ctDNA preprocedure or postprocedure was associated with inferior outcomes even after accounting for known prognostic clinicopathologic variables. This suggests ctDNA may enhance current risk stratification methods helping the evaluation of novel treatments and surveillance strategies toward improving patient outcomes.
Website
Google Scholar
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Data from Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment
by Aparna R. Parikh, Bryant H. Chee, Jill Tsai, Thereasa A. Rich, Kristin S. Price, Sonia A. Patel, Li Zhang, Faaiz Ibrahim, Mikaela Esquivel, Emily E. Van Seventer, et al.
Purpose:Minimal residual disease (MRD) detection can identify the recurrence in patients with colorectal cancer (CRC) following definitive treatment. We evaluated a plasma-only MRD assay to predict recurrence and survival in patients with metastatic CRC who underwent curative intent procedures (surgery and/or radiotherapy), with or without (neo)adjuvant chemotherapy. The primary objective of this study was to assess the correlation of postprocedure tumor cell–free DNA detection status with radiographic disease recurrence.Experimental Design:Preprocedure and postprocedure longitudinal samples were collected from 53 patients and analyzed with a multiomic MRD assay detecting circulating tumor DNA (ctDNA) from genomic and epigenomic signals. Preprocedure and postprocedure ctDNA detection correlated with recurrence-free and overall survival (OS).Results:From 52 patients, 230/233 samples were successfully analyzed. At the time of data cutoff, 36 (69.2%) patients recurred with median follow-up of 31 months. Detectable ctDNA was observed in 19/42 patients (45.2%) with ctDNA analyzed 3 weeks postprocedure. ctDNA detection 3 weeks postprocedure was associated with shorter median recurrence-free survival (RFS; HR, 5.27; 95% CI, 2.31–12.0; P < 0.0001) and OS (HR, 12.83; 95% CI, 3.6–45.9; P < 0.0001). Preprocedure ctDNA detection status was not associated with RFS but was associated with improved OS (HR, 4.65; 95% CI, 1.4–15.2; P = 0.0111). Undetectable ctDNA preprocedure had notable long-term OS, >90% 3 years postprocedure.Conclusions:In this cohort of oligometastatic CRC, detection of ctDNA preprocedure or postprocedure was associated with inferior outcomes even after accounting for known prognostic clinicopathologic variables. This suggests ctDNA may enhance current risk stratification methods helping the evaluation of novel treatments and surveillance strategies toward improving patient outcomes.
Open Access
Website
Google Scholar
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment
by Aparna R. Parikh, Bryant H. Chee, Jill Tsai, Thereasa A. Rich, Kristin S. Price, Sonia A. Patel, Li Zhang, Faaiz Ibrahim, Mikaela Esquivel, Emily E. Van Seventer, et al.
Supplementary Figure S4. Survival outcomes and recurrence rates stratified by CEA status.
Website
Google Scholar
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S4 from Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment
by Aparna R. Parikh, Bryant H. Chee, Jill Tsai, Thereasa A. Rich, Kristin S. Price, Sonia A. Patel, Li Zhang, Faaiz Ibrahim, Mikaela Esquivel, Emily E. Van Seventer, et al.
Supplementary Figure S4. Survival outcomes and recurrence rates stratified by CEA status.
Open Access
Website
Google Scholar
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment
by Aparna R. Parikh, Bryant H. Chee, Jill Tsai, Thereasa A. Rich, Kristin S. Price, Sonia A. Patel, Li Zhang, Faaiz Ibrahim, Mikaela Esquivel, Emily E. Van Seventer, et al.
Supplementary Figure S3. ctDNA dynamic changes for patients pre-and post-curative intent therapy (CI) (left) or adjuvant chemotherapy (ACT) (right).
Website
Google Scholar
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S3 from Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment
by Aparna R. Parikh, Bryant H. Chee, Jill Tsai, Thereasa A. Rich, Kristin S. Price, Sonia A. Patel, Li Zhang, Faaiz Ibrahim, Mikaela Esquivel, Emily E. Van Seventer, et al.
Supplementary Figure S3. ctDNA dynamic changes for patients pre-and post-curative intent therapy (CI) (left) or adjuvant chemotherapy (ACT) (right).
Open Access
Website
Google Scholar
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment
by Aparna R. Parikh, Bryant H. Chee, Jill Tsai, Thereasa A. Rich, Kristin S. Price, Sonia A. Patel, Li Zhang, Faaiz Ibrahim, Mikaela Esquivel, Emily E. Van Seventer, et al.
Supplementary Figure S2. Kaplan-Meier curves for patients with pre-procedure ctDNA stratified by ctDNA status.
Website
Google Scholar
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S2 from Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment
by Aparna R. Parikh, Bryant H. Chee, Jill Tsai, Thereasa A. Rich, Kristin S. Price, Sonia A. Patel, Li Zhang, Faaiz Ibrahim, Mikaela Esquivel, Emily E. Van Seventer, et al.
Supplementary Figure S2. Kaplan-Meier curves for patients with pre-procedure ctDNA stratified by ctDNA status.
Open Access
Website
Google Scholar
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment
by Aparna R. Parikh, Bryant H. Chee, Jill Tsai, Thereasa A. Rich, Kristin S. Price, Sonia A. Patel, Li Zhang, Faaiz Ibrahim, Mikaela Esquivel, Emily E. Van Seventer, et al.
Supplementary Table S3. Univariate analysis by pre-operative ctDNA status. Depicted are multiple clinicopathologic variables analyzed by ctDNA status.
Website
Google Scholar
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S3 from Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment
by Aparna R. Parikh, Bryant H. Chee, Jill Tsai, Thereasa A. Rich, Kristin S. Price, Sonia A. Patel, Li Zhang, Faaiz Ibrahim, Mikaela Esquivel, Emily E. Van Seventer, et al.
Supplementary Table S3. Univariate analysis by pre-operative ctDNA status. Depicted are multiple clinicopathologic variables analyzed by ctDNA status.
Open Access
Website
Google Scholar
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment
by Aparna R. Parikh, Bryant H. Chee, Jill Tsai, Thereasa A. Rich, Kristin S. Price, Sonia A. Patel, Li Zhang, Faaiz Ibrahim, Mikaela Esquivel, Emily E. Van Seventer, et al.
Supplementary Figure S2. Kaplan-Meier curves for patients with pre-procedure ctDNA stratified by ctDNA status.
Website
Google Scholar
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S2 from Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment
by Aparna R. Parikh, Bryant H. Chee, Jill Tsai, Thereasa A. Rich, Kristin S. Price, Sonia A. Patel, Li Zhang, Faaiz Ibrahim, Mikaela Esquivel, Emily E. Van Seventer, et al.
Supplementary Figure S2. Kaplan-Meier curves for patients with pre-procedure ctDNA stratified by ctDNA status.
Open Access
Website
Google Scholar
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment
by Aparna R. Parikh, Bryant H. Chee, Jill Tsai, Thereasa A. Rich, Kristin S. Price, Sonia A. Patel, Li Zhang, Faaiz Ibrahim, Mikaela Esquivel, Emily E. Van Seventer, et al.
Supplementary Figure S3. ctDNA dynamic changes for patients pre-and post-curative intent therapy (CI) (left) or adjuvant chemotherapy (ACT) (right).
Website
Google Scholar
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S3 from Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment
by Aparna R. Parikh, Bryant H. Chee, Jill Tsai, Thereasa A. Rich, Kristin S. Price, Sonia A. Patel, Li Zhang, Faaiz Ibrahim, Mikaela Esquivel, Emily E. Van Seventer, et al.
Supplementary Figure S3. ctDNA dynamic changes for patients pre-and post-curative intent therapy (CI) (left) or adjuvant chemotherapy (ACT) (right).
Open Access
Website
Google Scholar
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment
by Aparna R. Parikh, Bryant H. Chee, Jill Tsai, Thereasa A. Rich, Kristin S. Price, Sonia A. Patel, Li Zhang, Faaiz Ibrahim, Mikaela Esquivel, Emily E. Van Seventer, et al.
Supplementary Table S3. Univariate analysis by pre-operative ctDNA status. Depicted are multiple clinicopathologic variables analyzed by ctDNA status.
Website
Google Scholar
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Table S3 from Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment
by Aparna R. Parikh, Bryant H. Chee, Jill Tsai, Thereasa A. Rich, Kristin S. Price, Sonia A. Patel, Li Zhang, Faaiz Ibrahim, Mikaela Esquivel, Emily E. Van Seventer, et al.
Supplementary Table S3. Univariate analysis by pre-operative ctDNA status. Depicted are multiple clinicopathologic variables analyzed by ctDNA status.
Open Access
Website
Google Scholar
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment
by Aparna R. Parikh, Bryant H. Chee, Jill Tsai, Thereasa A. Rich, Kristin S. Price, Sonia A. Patel, Li Zhang, Faaiz Ibrahim, Mikaela Esquivel, Emily E. Van Seventer, et al.
Supplementary Figure S4. Survival outcomes and recurrence rates stratified by CEA status.
Website
Google Scholar
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open Access
Supplementary Figure S4 from Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment
by Aparna R. Parikh, Bryant H. Chee, Jill Tsai, Thereasa A. Rich, Kristin S. Price, Sonia A. Patel, Li Zhang, Faaiz Ibrahim, Mikaela Esquivel, Emily E. Van Seventer, et al.
Supplementary Figure S4. Survival outcomes and recurrence rates stratified by CEA status.

Show all